Hennion & Walsh Asset Management Inc. raised its position in Urogen Pharma (NASDAQ:URGN – Free Report) by 50.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 276,696 shares of the company’s stock after acquiring an additional 93,192 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.57% of Urogen Pharma worth $10,182,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of URGN. Swiss National Bank purchased a new position in Urogen Pharma during the 1st quarter worth approximately $1,399,000. SG Americas Securities LLC lifted its stake in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after buying an additional 280,199 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in Urogen Pharma by 139.1% in the first quarter. ADAR1 Capital Management LLC now owns 395,459 shares of the company’s stock valued at $7,110,000 after buying an additional 230,084 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of Urogen Pharma by 8.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock valued at $6,602,000 after acquiring an additional 22,733 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $2,342,000. 91.29% of the stock is owned by hedge funds and other institutional investors.
Urogen Pharma Trading Up 3.0%
NASDAQ:URGN opened at $46.96 on Friday. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $48.19. The stock’s 50 day simple moving average is $36.44 and its 200-day simple moving average is $27.12. The firm has a market cap of $2.30 billion, a P/E ratio of -23.72 and a beta of 1.57.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on URGN. Guggenheim lifted their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen increased their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Urogen Pharma has an average rating of “Moderate Buy” and an average target price of $48.78.
Get Our Latest Stock Report on URGN
Insider Activity at Urogen Pharma
In other news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider owned 119,763 shares in the company, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is currently owned by company insiders.
Urogen Pharma News Summary
Here are the key news stories impacting Urogen Pharma this week:
- Positive Sentiment: HC Wainwright significantly raised its FY2026 EPS forecast to a loss of $0.83 from a loss of $1.70. The firm also narrowed projected Q3 2026 and Q4 2026 losses to $0.07 and $0.01 per share, respectively. HC Wainwright FY2026 estimate update
- Positive Sentiment: The analyst now expects UroGen to reach profitability earlier than previously forecast, with estimates of $0.01 EPS in Q1 2027 and $0.17 EPS in Q2 2027, compared with prior loss estimates of $0.26 and $0.02 per share. HC Wainwright 2027 quarterly estimate update
- Positive Sentiment: HC Wainwright more than doubled its FY2027 EPS forecast to $1.05 from $0.50, while raising its Q3 2027 estimate to $0.36 from $0.28 and Q4 2027 to $0.50 from $0.49. These revisions strengthen the expected long-term earnings outlook. HC Wainwright FY2027 estimate update
- Neutral Sentiment: UroGen’s latest quarterly revenue of $72.46 million exceeded the $63.55 million consensus estimate, although its $0.28-per-share loss was slightly worse than the expected $0.26 loss. The mixed result makes the improved forward estimates particularly important to investors.
Urogen Pharma Company Profile
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.
The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.
Read More
- Five stocks we like better than Urogen Pharma
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
